Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.

Clinical pharmacokinetics - 1 Jul 2013

Moltó José, Xinarianos George, Miranda Cristina, Pushpakom Sudeep, Cedeño Samandhy, Clotet Bonaventura, Owen Andrew, Valle Marta

Abstract excerpt

BACKGROUND: Darunavir is a potent protease inhibitor of HIV. To enhance its pharmacokinetic profile, darunavir must be co-administered with ritonavir. There is wide inter-patient variability in darunavir pharmacokinetics among HIV-infected individuals, however. Darunavir is a known substrate for influx transporters, such as the 1A2 and the 1B1 members of the solute carrier organic anion transporter family...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Models, Biological

Share to Organic Anion Transporters

Share to Ritonavir

Share to Sulfonamides

Source

Identifiers

PMID: 23494984
DOI: 10.1007/s40262-013-0057-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.PMID 23494984Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Semantic proximity Read ↗

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

A population pharmacokinetic-pharmacogenetic analysis of atazanavir.Semantic proximity Read ↗

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Semantic proximity Read ↗

Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.